Tate & Lyle

Rising Health Trends And Urbanization Will Expand Specialty Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 11 Analysts

Published

30 Jun 25

AnalystHighTarget's Fair Value

UK£8.20

38.4% undervalued

10 Sep

UK£5.05

-25.1%

-1.6%

-25.1%

-1.6%

Edit anytime before Jun 30 9:24 PM. Then post Updates to your followers.

Author's Valuation

UK£8.2

38.4% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

UK£8.2

38.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.22%

Food revenue growth rate

0.13%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.82%

Calculation

UK£285.19m

Earnings '28

18.96x

PE Ratio '28

UK£5.41b

Market Cap '28

UK£5.41b

Market Cap '28

541.06m

No. shares '28

UK£9.99

Share Price '28

UK£9.99 Share Price '28

Discounted to 2025 @ 6.82% p.a.

UK£8.20

Fair Value '25